V. Mitsura

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

C. Leen, A. Mocroft, O. Kirk, 2017, HIV medicine.

Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study

A. Mocroft, O. Kirk, J. González, 2021, BMC Infectious Diseases.

Observational cohort study of rilpivirine (RPV) utilization in Europe

C. Leen, A. Mocroft, R. Paredes, 2022, AIDS Research and Therapy.

Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis

A. Mocroft, O. Kirk, J. Lundgren, 2014, AIDS.

Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Karin J. Metzner, Huldrych F. Günthard, E. Nicastri, 2014, The Journal of antimicrobial chemotherapy.

Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected?

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012 .

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Dynamics of Changing Attitude of Medical Students to People Living with HIV (Results of Prospective Study for 2012-2018)

A. N. Volchenko, V. Mitsura, E. A. Mosunova, 2018, Health and Ecology Issues.

Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?

A. Mocroft, J. Gatell, P. Reiss, 2017, AIDS.

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression

A. Mocroft, R. Paredes, C. Pedersen, 2014, Journal of the International AIDS Society.

Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

A. Mocroft, A. Blaxhult, J. Lundgren, 2018, HIV medicine.